# Virax Biolabs (VRAX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/VRAX
## Company Profile
- Ticker: VRAX
- Exchange: NASDAQ
- Sector: MedTech
- Location: United Kingdom and listed in the U
- Tags: Diagnostics
## Stock Data
- Close: 2.56 USD
- Market cap: 1605688.3416 USD
- Last updated: 2026-09-03
## Business Overview
Virax Biolabs is a diagnostics company focused on immune profiling and infectious-disease testing. Its business is centered on molecular and laboratory diagnostics rather than therapeutics.
## Why The Stock Is Moving

As of Sep 3, 2026, VRAX closed up 0.59% at $2.56. No new same-company headline was identified in the current news window.

## Geographic Base

Virax Biolabs is headquartered in the United Kingdom and listed in the U.S. market. It sits in diagnostics and medical devices rather than biotechnology.

## Business Model

The company depends on product adoption, test utilization, and commercialization in a competitive diagnostics market. Investors watch market access, product rollout, and operating execution.

## Landscape Position

Virax occupies the diagnostics layer of the healthcare stack. It is not a biotech drug name, but it belongs to the broader testing infrastructure that supports care decisions.

## Future Catalysts

- Virax’s catalysts are infectious-disease and immune-profiling programs, plus any update that shows the platform can still create value. The next step matters because the company remains early.

## Recent News
- 2026-07-16 11:30 EST — [Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement](https://biopharmsignal.com/news/VRAX/virax-biolabs-ceo-james-foster-provides-shareholder-update-following-fiscal-2026-e1b97d68) — Source: Virax Biolabs
- 2026-07-10 20:05 EST — [Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds](https://biopharmsignal.com/news/VRAX/virax-biolabs-group-limited-announces-closing-of-exercise-of-preferred-investmen-cc034f76) — Source: Virax Biolabs
- 2026-07-09 17:35 EST — [Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds](https://biopharmsignal.com/news/VRAX/virax-biolabs-group-limited-announces-exercise-of-preferred-investment-options-f-60095931) — Source: Virax Biolabs
- 2026-07-09 11:30 EST — [Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics](https://biopharmsignal.com/news/VRAX/virax-biolabs-signs-multi-country-commercial-supply-agreement-with-fosun-diagnos-d54171ee) — Source: Virax Biolabs
- 2026-06-24 13:00 EST — [Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation](https://biopharmsignal.com/news/VRAX/virax-biolabs-group-limited-announces-1-for-25-share-consolidation-aa5a26d6) — Source: Virax Biolabs